

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-14 (canceled).

Claim 15. (new): A method for treating a psychostimulant addiction, said method comprising administering to a individual in need of such treatment a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline as a partial dopamine agonist in the form of free base or in the form of pharmaceutically acceptable acid addition salt.

Claim 16. (new): A method for reducing or eliminating an abstinence symptom resulting from a withdrawal of a psychostimulant, said method comprising administering to a individual in need of such treatment a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline as a partial dopamine agonist in the form of free base or in the form of pharmaceutically acceptable acid addition salt.

Claim 17. (new): A method for reducing or eliminating a craving resulting from a withdrawal of a psychostimulant, said method comprising administering to a individual in need of such treatment a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline as a partial dopamine agonist in the form of free base or in the form of pharmaceutically acceptable acid addition salt.

Claim 18. (new): The method according to Claim 15, wherein the psychostimulant is selected from the group consisting of cocaine, amphetamine, methamphetamine, dextroamphetamine, 3,4-methylenedioxymethamphetamine, and pemoline, in the form of free base or in the form of a pharmaceutically acceptable acid addition salt.

Claim 19. (new): A pharmaceutical composition comprising 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt.

Claim 20. (new): The method according to Claim 15, wherein the psychostimulant addiction is cocaine addiction.

Claim 21. (new): The method according to Claim 16, wherein the psychostimulant is cocaine.

Claim 22. (new): The method according to Claim 17, wherein the psychostimulant is cocaine.

Claim 23. (new): The method according to Claim 15, wherein the 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline is in the form of a bimaleate salt.

Claim 24. (new): The method according to Claim 15, wherein the 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of a free base or in the form of pharmaceutically acceptable acid addition salt is present in an amount from about 0.05 to about 20 mg.

Claim 25. (new): The method according to Claim 24, wherein the amount is from 0.1 to 5.0 mg.

Claim 26. (new): The composition according to Claim 19 which additionally comprises a pharmaceutically acceptable carrier.

Claim 27. (new): The composition according to Claim 26 wherein the 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt is present in an amount of from about 0.05 to about 20 mg.

Claim 28. (new): The composition according to Claim 27, wherein the amount is from 0.1 to 5.0 mg.

Claim 29. (new): A method for treating cocaine addiction in an individual in need of such treatment, said method comprising administering the composition according to Claim 26.